Diplomat Pharmacy (DPLO) Lifted to “Outperform” at Leerink Swann
Leerink Swann upgraded shares of Diplomat Pharmacy (NYSE:DPLO) from a market perform rating to an outperform rating in a research note issued to investors on Monday, Marketbeat.com reports. Leerink Swann currently has $23.00 price target on the stock. Leerink Swann also issued estimates for Diplomat Pharmacy’s Q4 2017 earnings at $0.18 EPS, FY2017 earnings at $0.86 EPS, Q1 2018 earnings at $0.22 EPS, Q2 2018 earnings at $0.22 EPS, Q3 2018 earnings at $0.22 EPS, Q4 2018 earnings at $0.23 EPS, FY2018 earnings at $0.90 EPS and FY2019 earnings at $1.05 EPS.
A number of other equities research analysts have also recently weighed in on DPLO. BidaskClub raised Diplomat Pharmacy from a sell rating to a hold rating in a research note on Friday, September 15th. Robert W. Baird reaffirmed a buy rating and issued a $20.00 price objective on shares of Diplomat Pharmacy in a research note on Sunday, September 17th. Needham & Company LLC reaffirmed a buy rating and issued a $23.75 price objective (up from $19.75) on shares of Diplomat Pharmacy in a research note on Wednesday, October 4th. Zacks Investment Research raised Diplomat Pharmacy from a hold rating to a strong-buy rating and set a $24.00 price objective for the company in a research note on Tuesday, October 10th. Finally, Mizuho set a $16.00 price objective on Diplomat Pharmacy and gave the company a hold rating in a research note on Tuesday, October 24th. Five investment analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Diplomat Pharmacy has an average rating of Buy and an average target price of $20.72.
Shares of Diplomat Pharmacy (NYSE DPLO) opened at $20.26 on Monday. The company has a debt-to-equity ratio of 0.18, a quick ratio of 0.82 and a current ratio of 1.34. The stock has a market capitalization of $1,368.51, a price-to-earnings ratio of 25.81, a price-to-earnings-growth ratio of 3.58 and a beta of 0.61. Diplomat Pharmacy has a one year low of $12.25 and a one year high of $21.99.
Diplomat Pharmacy (NYSE:DPLO) last issued its quarterly earnings data on Monday, November 6th. The company reported $0.25 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.15 by $0.10. Diplomat Pharmacy had a return on equity of 8.30% and a net margin of 0.18%. The business had revenue of $1.12 billion during the quarter, compared to analysts’ expectations of $1.16 billion. During the same period in the previous year, the firm posted $0.21 earnings per share. The company’s revenue was down 4.8% on a year-over-year basis. equities analysts expect that Diplomat Pharmacy will post 0.85 EPS for the current year.
In related news, Director Jeffrey G. Park bought 3,000 shares of the stock in a transaction that occurred on Monday, November 20th. The stock was purchased at an average cost of $15.46 per share, with a total value of $46,380.00. Following the purchase, the director now directly owns 7,640 shares of the company’s stock, valued at approximately $118,114.40. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Atul Kavthekar bought 2,000 shares of the stock in a transaction that occurred on Monday, November 20th. The shares were bought at an average cost of $15.00 per share, with a total value of $30,000.00. Following the completion of the purchase, the chief financial officer now directly owns 2,000 shares in the company, valued at $30,000. The disclosure for this purchase can be found here. Insiders have purchased a total of 15,000 shares of company stock valued at $228,780 over the last three months. 30.20% of the stock is currently owned by insiders.
A number of hedge funds and other institutional investors have recently made changes to their positions in DPLO. PNC Financial Services Group Inc. lifted its holdings in Diplomat Pharmacy by 46.7% during the 2nd quarter. PNC Financial Services Group Inc. now owns 8,779 shares of the company’s stock worth $130,000 after buying an additional 2,794 shares during the last quarter. Municipal Employees Retirement System of Michigan increased its position in Diplomat Pharmacy by 4.9% during the 2nd quarter. Municipal Employees Retirement System of Michigan now owns 10,250 shares of the company’s stock worth $152,000 after purchasing an additional 480 shares during the period. Janney Montgomery Scott LLC increased its position in Diplomat Pharmacy by 11.9% during the 2nd quarter. Janney Montgomery Scott LLC now owns 11,193 shares of the company’s stock worth $166,000 after purchasing an additional 1,193 shares during the period. Bank of Montreal Can increased its position in Diplomat Pharmacy by 3.0% during the 2nd quarter. Bank of Montreal Can now owns 11,600 shares of the company’s stock worth $172,000 after purchasing an additional 340 shares during the period. Finally, Trexquant Investment LP acquired a new position in Diplomat Pharmacy during the 2nd quarter worth approximately $180,000. 72.48% of the stock is owned by institutional investors.
Diplomat Pharmacy Company Profile
Diplomat Pharmacy, Inc (Diplomat) operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company operates through specialty pharmacy services segment. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialty infusion therapy, and various other serious and/or long-term conditions.
Receive News & Ratings for Diplomat Pharmacy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy and related companies with Analyst Ratings Network's FREE daily email newsletter.